Research Studies

Browse Studies

Elevate-PD

Upcoming
Conditions:
PD

Criteria

Ages
18+
Cognition
Dyskinesias
any
Fluctuations
Yes
Tremor
Gait
DBS
No
Hallucinations

About this study

The main purpose of this study is to see how effective and safe CREXONT® is for people with Parkinson’s disease (PD) in everyday life. CREXONT is a combination of levodopa (LD) and carbidopa (CD) used to treat PD. It was approved by the Food and Drug Administration (FDA) in August 2024.

Sustain our mission to enhance lives and outcomes through research

As we work to improve patient quality of life — for their entire lifespan — we seek partners to catapult our progress. With your philanthropic investment, we can expand the breadth and depth of our efforts in three critical areas: research, clinical care and education and training.

Support Us